MARTELLI, MARGHERITA
 Distribuzione geografica
Continente #
NA - Nord America 491
EU - Europa 317
AS - Asia 179
AF - Africa 29
OC - Oceania 1
Totale 1.017
Nazione #
US - Stati Uniti d'America 490
IT - Italia 84
GB - Regno Unito 66
DE - Germania 53
SG - Singapore 51
SE - Svezia 44
CN - Cina 42
VN - Vietnam 41
IE - Irlanda 27
IN - India 24
TG - Togo 16
JO - Giordania 12
FR - Francia 10
RU - Federazione Russa 7
NG - Nigeria 6
ZA - Sudafrica 5
BG - Bulgaria 4
CH - Svizzera 4
UA - Ucraina 4
EE - Estonia 3
HK - Hong Kong 3
PL - Polonia 3
CI - Costa d'Avorio 2
DK - Danimarca 2
FI - Finlandia 2
LB - Libano 2
NL - Olanda 2
AL - Albania 1
AT - Austria 1
AU - Australia 1
CA - Canada 1
IQ - Iraq 1
IR - Iran 1
KR - Corea 1
TR - Turchia 1
Totale 1.017
Città #
Chandler 99
Southend 62
Singapore 46
Dong Ket 41
Fairfield 40
Dublin 27
Woodbridge 25
Ashburn 24
Princeton 22
Seattle 22
Wilmington 22
Redmond 20
Houston 19
Bologna 16
Lomé 16
Cambridge 13
Amman 12
Turin 12
Ann Arbor 8
Berlin 8
Des Moines 7
Abeokuta 6
Milan 6
Westminster 6
Nanjing 5
Beijing 4
Bern 4
Florence 4
Medford 4
New York 4
Santa Clara 4
Shenyang 4
Sofia 4
Boydton 3
Brescia 3
Padova 3
Saint Petersburg 3
San Diego 3
Warsaw 3
Abidjan 2
Albignasego 2
Bremen 2
Cernusco sul Naviglio 2
Cesena 2
Deventer 2
Ferrara 2
Forlì 2
Frederiksberg 2
Gaomi 2
Hebei 2
Helsinki 2
Latina 2
Los Angeles 2
Mogliano Veneto 2
Munich 2
Olalla 2
Rome 2
Siena 2
Tianjin 2
Venice 2
Zhengzhou 2
Ankara 1
Argelato 1
Bangalore 1
Beirut 1
Bühl 1
Catania 1
Changsha 1
Chicago 1
Easton 1
Foshan 1
Francofonte 1
Frankfurt am Main 1
Guangzhou 1
Hangzhou 1
Harbin 1
Hyderabad 1
Jinan 1
Lanzhou 1
London 1
Mountain View 1
Nanchang 1
North Bergen 1
Norwalk 1
Novokuznetsk 1
Nürnberg 1
Regensburg 1
San Francisco 1
Sassari 1
Seoul 1
Serio 1
Stockholm 1
Suzhou 1
Taicang 1
Taizhou 1
Tirana 1
Toronto 1
Vienna 1
Xi'an 1
Totale 716
Nome #
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 125
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 112
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 112
BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now? 103
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 99
Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells 89
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 79
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 75
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 75
Recent advances in the molecular biology of systemic mastocytosis: Implications for diagnosis, prognosis, and therapy 72
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update 67
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 52
Totale 1.060
Categoria #
all - tutte 3.393
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.393


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020102 0 0 0 6 16 9 14 12 12 13 9 11
2020/2021187 17 7 0 4 1 2 16 36 20 6 17 61
2021/2022186 7 0 15 7 20 15 4 15 10 14 43 36
2022/2023328 33 46 7 39 27 21 19 9 66 10 41 10
2023/202467 3 16 9 11 4 10 2 3 1 4 3 1
2024/2025130 19 68 40 3 0 0 0 0 0 0 0 0
Totale 1.060